David Cohen Sells 6,056 Shares of Evommune (NYSE:EVMN) Stock

Posted by George Bondi on Jun 5th, 2026

Evommune, Inc. (NYSE:EVMN – Get Free Report) Director David Cohen sold 6,056 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $20.33, for a total transaction of $123,118.48. Following the completion of the sale, the director owned 17,609 shares of the company’s stock, valued at $357,990.97. The trade was a 25.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Evommune Price Performance

NYSE:EVMN opened at $20.78 on Friday. The firm has a market capitalization of $748.57 million and a PE ratio of -2.19. The business has a fifty day moving average of $23.97. Evommune, Inc. has a 12 month low of $13.89 and a 12 month high of $33.20.

Evommune (NYSE:EVMN – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.19. On average, research analysts forecast that Evommune, Inc. will post -2.86 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Capricorn Fund Managers Ltd bought a new position in shares of Evommune during the fourth quarter valued at about $1,027,000. Sectoral Asset Management Inc. bought a new position in shares of Evommune during the fourth quarter valued at about $10,084,000. Seven Grand Managers LLC bought a new position in shares of Evommune during the fourth quarter valued at about $1,284,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Evommune during the fourth quarter valued at about $34,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Evommune during the first quarter valued at about $508,000.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Stifel Nicolaus assumed coverage on shares of Evommune in a report on Friday, May 1st. They set a “buy” rating and a $54.00 price objective for the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $48.00 price objective on shares of Evommune in a report on Friday, April 10th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Evommune in a report on Tuesday, May 26th. Evercore reiterated an “outperform” rating and set a $55.00 price objective on shares of Evommune in a report on Tuesday, February 10th. Finally, Oppenheimer started coverage on shares of Evommune in a report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $49.25.

Get Our Latest Analysis on EVMN

About Evommune

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.